Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Bryce · SciRah

Researcher profile · Semantic Scholar

A. Bryce

Share profile

A. Bryce — researcher profile on SciRah

h-index: 42
Works: 249
Citations: 22K

Most-cited papers

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
K. Fizazi, J. Piulats, M. Reaume, P. Ostler +24 more
2023New England Journal of Medicine333 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
E. Schaeffer, S. Srinivas, N. Adra, Y. An +34 more
2022The Journal of the National Comprehensive Cancer Network196 citations
Semantic Scholar
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
I. Bin Riaz, S. Naqvi, Huan He, Noureen Asghar +11 more
2023JAMA Oncology122 citations Open access
Semantic Scholar
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
W. Abida, D. Campbell, A. Patnaik, A. Bryce +26 more
2023European Urology108 citations Open access
Semantic Scholar
FOXA1 overexpression suppresses interferon signaling and immune response in cancer.
Yun-Dong He, Li-Guo Wang, Ting Wei, Yu-Tian Xiao +25 more
2021Journal of Clinical Investigation86 citations Open access
Semantic Scholar
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
A. Mansfield, D. Hong, C. Hann, A. Farago +16 more
2021npj Precision Oncology62 citations Open access
Semantic Scholar
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
A. Loehr, A. Hussain, A. Patnaik, A. Bryce +17 more
2022European Urology61 citations Open access
Semantic Scholar
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.
I. Bin Riaz, Mahnoor Islam, W. Ikram, S. Naqvi +16 more
2022JAMA Oncology56 citations Open access
Semantic Scholar
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer
M. G. Velez, H. Kosiorek, J. Egan, Andrea McNatty +9 more
2021Prostate Cancer and Prostatic Diseases51 citations Open access
Semantic Scholar
Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer
K. K. Budhraja, B. McDonald, M. D. Stephens, T. Contente-Cuomo +18 more
2023Science Translational Medicine50 citations Open access
Semantic Scholar
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
F. Taza, Albert E. Holler, W. Fu, Hao Wang +22 more
2021JCO Precision Oncology45 citations Open access
Semantic Scholar
Assessment of Isochromosome 12p & 12p Abnormalities in Germ Cell Tumors Using FISH, SNP-Arrays & NGS/ Mate-Pair Sequencing.
C. E. Freitag, W. Sukov, A. Bryce, J. Berg +16 more
2021Human Pathology40 citations
Semantic Scholar
Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach
Suryadipto Sarkar, Kong Min, W. Ikram, Ryan Tatton +9 more
2023Cancers37 citations Open access
Semantic Scholar
Disparities in Representation of Women, Older Adults and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials.
I. Riaz, Mahnoor Islam, A. Khan, S. Naqvi +12 more
2022American Journal of Medicine27 citations
Semantic Scholar
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
M. Morris, G. Heller, D. Hillman, Olivia J Bobek +19 more
2023Journal of Clinical Oncology26 citations Open access
Semantic Scholar
Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours
D. Karp, D. Camidge, J. Infante, T. Ames +3 more
2022EClinicalMedicine23 citations Open access
Semantic Scholar
Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study
A. Loehr, A. Patnaik, D. Campbell, J. Shapiro +24 more
2021Clinical Cancer Research22 citations Open access
Semantic Scholar
TEMPORARY REMOVAL: Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
I. Bin Riaz, H. Fuentes, Syed Arsalan Ahmed Naqvi, Huan He +12 more
2021Mayo Clinic proceedings18 citations
Semantic Scholar
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
E. Francini, F. Montagnani, P. Nuzzo, M. Gonzalez-Velez +18 more
2021JAMA Network Open18 citations Open access
Semantic Scholar
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study
C. Eule, Jun-Xiao Hu, Sulaiman Al-Saad, K. Collier +10 more
2023Clinical Genitourinary Cancer16 citations Open access
Semantic Scholar
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
R. Aggarwal, J. Alumkal, R. Szmulewitz, C. Higano +8 more
2022Prostate Cancer16 citations Open access
Semantic Scholar
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
A. Bryce, J. Piulats, M. Reaume, P. Ostler +16 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
Radiotherapy in Oligometastatic Prostate Cancer.
S. Chinniah, B. Stish, B. Costello, L. Pagliaro +6 more
2022International Journal of Radiation Oncology, Biology, Physics15 citations Open access
Semantic Scholar
Molecular profile changes in castrate resistant prostate cancer patients pre and post-abiraterone/prednisone treatment
H. Sicotte, K. Kalari, S. Qin, S. Dehm +13 more
2022Molecular Cancer Research14 citations Open access
Semantic Scholar
Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer
C. Ng, Hilda M. Gonzalez Bonilla, A. Bryce, Parminder Singh +1 more
2023Current Cardiology Reports13 citations
Semantic Scholar
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
Christopher T Su, E. Nizialek, J. Berchuck, P. Vlachostergios +18 more
2022The Prostate13 citations Open access
Semantic Scholar
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers
A. Bryce, D. Thiel, M. Seiden, D. Richards +7 more
2023JCO Precision Oncology12 citations Open access
Semantic Scholar
A Clinician's Guide to Targeted Precision Imaging in Patients With Prostate Cancer (RADAR VI)
E. Crawford, D. Albala, R. Harris, S. Slovin +14 more
2022JU Open Plus12 citations Open access
Semantic Scholar
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases
Alex J. Liu, H. Kosiorek, B. Ueberroth, E. Jaeger +12 more
2022The Prostate12 citations
Semantic Scholar
Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
S. Naqvi, Z. Bin Riaz, A. Riaz, Mahnoor Islam +7 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration-resistant prostate cancer
S. Qin, Huan-Yao Gao, Wootae Kim, Huan-Ji Zhang +14 more
2022Clinical pharmacology and therapy10 citations Open access
Semantic Scholar
Association Between Baseline Body Mass Index and Survival in Men with Metastatic Hormone Sensitive Prostate Cancer: ECOG-ACRIN CHAARTED E3805
A. Morgans, Yu-Hui Chen, D. Jarrard, M. Carducci +13 more
2022The Prostate10 citations Open access
Semantic Scholar
Analysis of fragment ends in plasma DNA from patients with cancer
Karan K. Budhraja, B. McDonald, M. D. Stephens, Tania Contente-Cuomo +18 more
2021medRxiv8 citations Open access
Semantic Scholar
Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
S. Naqvi, I. Bin Riaz, Manal Imran, M. D. Bin Zafar +4 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
B. Labadie, David S. Morris, A. Bryce, R. Given +4 more
2022Cancer Management and Research6 citations Open access
Semantic Scholar
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies
Zhuoer Xie, Antoine N. Saliba, J. Abeykoon, U. Majeed +25 more
2021JCO Oncology Practice6 citations Open access
Semantic Scholar
Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma
Holly M Thomson, Shannon P. Fortin Ensign, V. Edmonds, Amit Kumar Sharma +9 more
2023Clinical Medicine Insights: Oncology5 citations Open access
Semantic Scholar
The prognostic value of androgen to PSA ratio in predictive modeling of prostate cancer
Tin Phan, Allison Weber, A. Bryce, Yang Kuang
2023Medical Hypotheses5 citations
Semantic Scholar
LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
R. Aggarwal, G. Heller, D. Hillman, Han Xiao +16 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis.
I. Bin Riaz, Qurat-ul-Ain Riaz Sipra, S. Naqvi, Huan He +12 more
2022Critical reviews in oncology/hematology5 citations
Semantic Scholar
Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
M. Jimbo, J. Andrews, Mohamed E. Ahmed, A. Dundar +6 more
2021The Prostate5 citations
Semantic Scholar
Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
R. Aggarwal, G. Heller, D. Hillman, Han Xiao +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
Grant P Rauterkus, A. Hadadi, R. Barnett, C. Weipert +7 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial
P. LoRusso, A. Sekulic, J. Sosman, W. Liang +43 more
2021PLoS ONE4 citations Open access
Semantic Scholar
Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
M. Moussa, S. Naqvi, Jaanki Khandelwal, M. Campbell +5 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.
Miguel Muniz, A. Sartor, Ahmed M. Mahmoud, Jacob J. Orme +12 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.
Muhammad Ali Khan, S. Naqvi, Manal Imran, Aneeta Channar +13 more
2024Journal of Clinical Oncology3 citations Open access
Semantic Scholar
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
S. Naqvi, I. Bin Riaz, Huan He, Manal Imran +6 more
2023Journal of Clinical Oncology3 citations Open access
Semantic Scholar
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
A. Bryce, D. Karp, S. Tagawa, L. Nordquist +9 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
M. Parikh, C. Tangen, M. Hussain, Shilpa Gupta +16 more
2023Journal of Clinical Oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Parminder Singh×11
Invite
Parminder Singh — researcher profile on SciRah
S. Naqvi×10
Invite
S. Naqvi — researcher profile on SciRah
I. Bin Riaz×9
Invite
I. Bin Riaz — researcher profile on SciRah
W. Abida×6
Invite
W. Abida — researcher profile on SciRah

×6

Invite

S. Chowdhury — researcher profile on SciRah

Invite

B. Sautois — researcher profile on SciRah

Invite

A. Loehr — researcher profile on SciRah

Invite

D. Despain — researcher profile on SciRah

Invite

S. Watkins — researcher profile on SciRah

Invite

T. Dorff — researcher profile on SciRah

Invite

P. Ravi — researcher profile on SciRah

Invite

A. Patnaik — researcher profile on SciRah